# Corcept Therapeutics Inc: overview

CORT · Nasdaq · CIK 1088856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cort.md) · [Financials](/companies/cort/financials.md) · [Filings](/companies/cort/filings.md) · [Insiders](/companies/cort/insiders.md)

Latest reported revenue: [$256.1m](/filings/0001628280-26-050613.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-050613).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [183](/filings/0001628280-25-048841.md) | [182 d](/filings/0001628280-26-011091.md) | [157](/filings/0001628280-26-028902.md) | [194](/filings/0001628280-26-050613.md) | [208](/filings/0001628280-25-048841.md) | [202 d](/filings/0001628280-26-011091.md) | [165](/filings/0001628280-26-028902.md) | [256](/filings/0001628280-26-050613.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [25.5%](/filings/0001628280-25-048841.md) | [13.9% d](/filings/0001628280-26-011091.md) | [2.2%](/filings/0001628280-26-028902.md) | [13.7%](/filings/0001628280-26-050613.md) | [4.9%](/filings/0001628280-25-048841.md) | [2.2% d](/filings/0001628280-26-011091.md) | [(30.1%)](/filings/0001628280-26-028902.md) | [16.1%](/filings/0001628280-26-050613.md) |
| Net margin | % | [25.9%](/filings/0001628280-25-048841.md) | [16.9% d](/filings/0001628280-26-011091.md) | [13.1%](/filings/0001628280-26-050613.md) | [18.1%](/filings/0001628280-26-050613.md) | [9.5%](/filings/0001628280-25-048841.md) | [12.0% d](/filings/0001628280-26-011091.md) | [(19.3%)](/filings/0001628280-26-050613.md) | [16.8%](/filings/0001628280-26-050613.md) |
| Diluted EPS | $ per share | [0.41](/filings/0001628280-25-048841.md) | not reported | [0.17](/filings/0001628280-26-028902.md) | [0.29](/filings/0001628280-26-050613.md) | [0.16](/filings/0001628280-25-048841.md) | not reported | [(0.30)](/filings/0001628280-26-028902.md) | [0.36](/filings/0001628280-26-050613.md) |
| Free cash flow | $m | [71.7 d](/filings/0001628280-25-048841.md) | [59.9 d](/filings/0001628280-26-011091.md) | [4.7](/filings/0001628280-26-028902.md) | [44.2 d](/filings/0001628280-26-050613.md) | [54.5 d](/filings/0001628280-25-048841.md) | [38.4 d](/filings/0001628280-26-011091.md) | [(17.0)](/filings/0001628280-26-028902.md) | [31.0 d](/filings/0001628280-26-050613.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [366](/filings/0001628280-24-005055.md) | [402](/filings/0001628280-25-008167.md) | [482](/filings/0001628280-26-011091.md) | [675](/filings/0001628280-26-011091.md) | [761](/filings/0001628280-26-011091.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [34.0%](/filings/0001628280-24-005055.md) | [28.0%](/filings/0001628280-25-008167.md) | [22.2%](/filings/0001628280-26-011091.md) | [20.3%](/filings/0001628280-26-011091.md) | [5.9%](/filings/0001628280-26-011091.md) |
| Net margin | % | [30.7%](/filings/0001628280-24-005055.md) | [25.2%](/filings/0001628280-25-008167.md) | [22.0%](/filings/0001628280-26-011091.md) | [20.9%](/filings/0001628280-26-011091.md) | [13.1%](/filings/0001628280-26-011091.md) |
| Diluted EPS | $ per share | [0.89](/filings/0001628280-24-005055.md) | [0.87](/filings/0001628280-25-008167.md) | [0.94](/filings/0001628280-26-011091.md) | [1.23](/filings/0001628280-26-011091.md) | [0.82](/filings/0001628280-26-011091.md) |
| Free cash flow | $m | [167](/filings/0001628280-24-005055.md) | [120](/filings/0001628280-25-008167.md) | [127](/filings/0001628280-26-011091.md) | [196](/filings/0001628280-26-011091.md) | [142](/filings/0001628280-26-011091.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cort/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.08bn | 12,432,023 |  | Added +280,747 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $457.5m | 5,261,628 |  | Reduced −421,155 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $438.6m | 5,044,638 |  | Added +224,070 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $362.8m | 4,172,482 |  | Added +95,286 |
| [Parallel Advisors, LLC](/funds/1690010.md) | 2026-06-30 | $344.5m | 3,962,177 |  | Reduced −15,227 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $290.2m | 3,337,618 |  | Added +147,426 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $285.2m | 3,279,381 |  | Added +78,435 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $224.6m | 2,582,561 |  | Added +2,176,356 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $220.2m | 2,532,198 |  | Reduced −181,321 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $159.1m | 1,829,545 |  | Reduced −343,831 |

## Recent filings

[All 1,543 filings](/companies/cort/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 08:15 ET | [8-K](/filings/0001193125-26-398561.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-398561 |
| 2026-07-29 | 16:09 ET | [10-Q](/filings/0001628280-26-050613.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050613 |
| 2026-07-29 | 16:07 ET | [8-K](/filings/0001628280-26-050607.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-050607 |
| 2026-06-17 | 16:36 ET | [8-K](/filings/0001193125-26-274258.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-274258 |
| 2026-06-03 | 08:00 ET | [8-K](/filings/0001193125-26-254622.md) | 8.01 Other events | 0001193125-26-254622 |
| 2026-05-28 | 16:04 ET | [8-K](/filings/0001628280-26-038793.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-038793 |
| 2026-04-30 | 16:14 ET | [10-Q](/filings/0001628280-26-028902.md) | Quarterly report, period 2026-03-31 | 0001628280-26-028902 |
| 2026-04-30 | 16:11 ET | [8-K](/filings/0001628280-26-028892.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-028892 |
| 2026-04-17 | 16:08 ET | [DEF 14A](/filings/0001628280-26-025735.md) | Proxy statement, period 2026-04-17 | 0001628280-26-025735 |
| 2026-03-25 | 13:31 ET | [8-K](/filings/0001193125-26-123543.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-123543 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011091.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/210386ca-8fb2-473a-b9f3-2e57d7e67d18)

## About the filer

- CIK: 1088856
- Tickers: CORT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. No prices; not investment advice.